Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

To say this has been a big year for Summit Therapeutics (NASDAQ: SMMT) would be a huge understatement. The stock has risen ...

This year, Summit Therapeutics Inc. (SMMT) leads the parade of winners among large stocks (those with a market value of $10 ...

On Monday, Summit Therapeutics Inc (SMMT) stock saw a modest uptick, ending the day at $21.77 which represents a slight increase of $0.36 or 1.68% from the prior close of $21.41. The stock opened at ...

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

On Thursday, Summit Therapeutics Inc (SMMT) stock saw a decline, ending the day at $18.59 which represents a decrease of $-0.06 or -0.32% from the prior close of $18.65. The stock opened at $18.75 and ...

Summit Therapeutics Inc's innovative approach to combating serious infectious diseases positions it as a potential leader in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Archived copies of the webcasts will be available for up to one year by visiting the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.

GOTHENBURG, SWEDEN / ACCESSWIRE / November 13, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, November ...

Presentation to highlight advances in fibrostenotic Crohn’s Disease and the potential of localized PDE4 inhibitionCarlsbad, CA, Nov. 14, 2024 ...

Join STAT to explore how the biopharma industry is advancing outcome-based multimodal therapeutics on Nov. 22.